Synaura Biotechnology(Shanghai) Co., Ltd. is headquartered in Zhangjiang, Shanghai. As a health technology enterprise driven by synthetic biology, Synaura focus on independent research, development and industrialisation of synthetic biological products such as Human Milk Oligosaccharides (HMOs). We are committed to overcoming key technological barriers and propelling China's independently developed functional ingredients onto the global stage.
Within a few short years, Synaura has established a comprehensive presence across HMO research, production, certification, and application, emerging as a leader within China's HMO industrial chain.

Simultaneously establish two research and development centers in Beijing and Shanghai, led by more than ten senior doctors in the field of material technology and more than 40 research elites to form a high-level innovation team. The R&D center is equipped with a world leading experimental platform, building four major R&D systems covering genetic engineering, precision fermentation, process pilot testing, and detection analysis. It has established a resource library of over 100000 synthetic biological components, forming a full chain innovation capability from molecular design to achievement transformation. In core areas such as biosynthesis, cell factories, and large-scale production, Hongge continues to achieve technological breakthroughs and has laid out multiple original HMO core technology routes such as 2 '- FL, 3' - SL, LNnT, etc., and has applied for more than 50 domestic and foreign patents. With continuous scientific research investment and innovative achievements, Hongye drives industrial innovation with the power of scientific research, accelerating the construction of a globally leading HMO innovation system.

China's first industrialised facility to obtain HMO food production certification, with multiple HMO product pipelines including 2'-FL, 3'-SL, LNnT, 6'-SL, and 3-FL. Leveraging pioneering fermentation and purification processes, it secured the world's first 99% high-purity HMO certification, achieving an initial annual production capacity of 500 tonnes. The Synaura Production Base has achieved full compliance with international certifications including ISO 22000, rigorously adheres to BP Pharmacopoeia standards, and strives to establish a comprehensive, traceable quality management system. This ensures product consistency and stability, setting new industry benchmarks through exceptional manufacturing practices.